Cargando…

Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial

This phase II/III, double-blind, randomized trial assessed the efficacy, immunogenicity and safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in young Chinese women (ClinicalTrials.gov registration NCT00779766). Women aged 18–25 years from Jiangsu province were randomized (1:1)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Feng-Cai, Chen, Wen, Hu, Yue-Mei, Hong, Ying, Li, Juan, Zhang, Xun, Zhang, Yi-Ju, Pan, Qin-Jing, Zhao, Fang-Hui, Yu, Jia-Xi, Zhang, Yan-Shu, Yang, Xiaoping, Zhang, Cheng-Fu, Tang, Haiwen, Zhang, Helen, Lebacq, Marie, David, Marie-Pierre, Datta, Sanjoy K, Struyf, Frank, Bi, Dan, Descamps, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Infectious Causes of Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277330/ https://www.ncbi.nlm.nih.gov/pubmed/24740596 http://dx.doi.org/10.1002/ijc.28897

Ejemplares similares

Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18–25 years enrolled in a clinical trial
por: Zhao, Fang-Hui, et al.
Publicado: (2014)

Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized controlled trial
por: Zhu, Feng‐cai, et al.
Publicado: (2016)

Assessment of herd effects among women and heterosexual men after girls‐only HPV16/18 vaccination in the Netherlands: A repeated cross‐sectional study
por: Woestenberg, Petra J, et al.
Publicado: (2018)

Dysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV‐related cervical carcinogenesis
por: Zhang, Ruiyang, et al.
Publicado: (2016)

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials
por: Zhu, Fengcai, et al.
Publicado: (2014)

Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study
por: Rachel Skinner, S., et al.
Publicado: (2016)

Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial
por: Zhu, Feng‐Cai, et al.
Publicado: (2019)

Evaluating HPV‐negative CIN2+ in the ATHENA trial
por: Petry, Karl Ulrich, et al.
Publicado: (2016)

Potential effectiveness of a therapeutic HPV intervention campaign in Uganda
por: Spencer, Jennifer C., et al.
Publicado: (2021)

Short half‐life of HPV16 E6 and E7 mRNAs sensitizes HPV16‐positive tonsillar cancer cell line HN26 to DNA‐damaging drugs
por: Wu, Chengjun, et al.
Publicado: (2018)

Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort
por: Bonde, Jesper, et al.
Publicado: (2019)

Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: A prospective cohort study
por: Liu, Tong, et al.
Publicado: (2021)

A bacterial genotoxin causes virus reactivation and genomic instability in Epstein–Barr virus infected epithelial cells pointing to a role of co‐infection in viral oncogenesis
por: Frisan, Teresa, et al.
Publicado: (2018)

Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial
por: Lehtinen, Matti, et al.
Publicado: (2019)

Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
por: Hu, Shangying, et al.
Publicado: (2020)

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
por: Schwarz, Tino F., et al.
Publicado: (2017)

The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States
por: Wheeler, Cosette M, et al.
Publicado: (2014)

Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study
por: Wakeham, Katie, et al.
Publicado: (2015)

Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response
por: Cosset, Érika, et al.
Publicado: (2014)

Human papillomavirus prevalence and type‐distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study
por: Holl, Katsiaryna, et al.
Publicado: (2015)

Cause‐specific mortality after diagnosis of cancer among HIV‐positive patients: A collaborative analysis of cohort studies
por: Trickey, Adam, et al.
Publicado: (2020)

Cutaneous viral infections associated with ultraviolet radiation exposure
por: Zhao, Yayi, et al.
Publicado: (2020)

The unveiled reality of human papillomavirus as risk factor for oral cavity squamous cell carcinoma
por: Nauta, Irene H., et al.
Publicado: (2021)

Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients
por: Starita, Noemy, et al.
Publicado: (2022)

Atypical glandular cells and development of cervical cancer: Population‐based cohort study
por: Norman, Ingrid, et al.
Publicado: (2022)

Differential etiopathogenic features of vulvar squamous cell carcinomas in sub‐Saharan Africa and Europe
por: Rakislova, Natalia, et al.
Publicado: (2022)

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial
por: Lehtinen, Matti, et al.
Publicado: (2016)

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial
por: Zhu, Feng-Cai, et al.
Publicado: (2011)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
por: Folschweiller, Nicolas, et al.
Publicado: (2020)

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women
por: Sow, Papa Salif, et al.
Publicado: (2013)

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2019)

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
por: Einstein, Mark H, et al.
Publicado: (2014)

Erratum to: Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2020)

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
por: Szarewski, Anne, et al.
Publicado: (2013)

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
por: Schwarz, Tino F., et al.
Publicado: (2019)

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
por: Romanowski, Barbara, et al.
Publicado: (2015)

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination
por: Naud, Paulo S, et al.
Publicado: (2014)

A First Publication by the International Labour Office
Publicado: (1921)

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial
por: Huang, Li-Min, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j39bvlj2n2h696u81vh2291mf9